Clinical Study of ET190L1 ARTEMIS™ in Relapsed, Refractory B Cell Lymphoma

NCT03415399 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

4

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma, B-Cell

Interventions

BIOLOGICAL: ET190L1 ARTEMIS™ T cells

Sponsor

Eureka Therapeutics Inc.

Collaborators

[object Object]